U.S. Food and Drug Administration - CDRH Mobile
Skip NavigationFDA Logo links to FDA home pageCenter for Devices and Radiological Health, U.S. Food and Drug AdministrationHHS Logo links to Department of Health and Human Services website
FDA Home Page | CDRH Home Page | Search | A-Z Index U.S. Food and Drug AdministrationCenter for Devices and Radiological Health Questions?
horizonal rule

FDA > CDRH > Medical Device Recalls > Class I Recall: Medtronic Neuromodulation SynchroMed EL, SynchroMed II and IsoMed Implantable Infusion Pumps

Class I Recall: Medtronic Neuromodulation SynchroMed EL, SynchroMed II and IsoMed Implantable Infusion Pumps

Date Recall
Initiated

January 16, 2008
Product:

Medtronic Neuromodulation Implantable Infusion Pumps:

  • SynchroMed EL Implantable Infusion Pump, Models 8626-10, 8626-18, 8626L-10, 8626L-18, 8627-10, 8627-18, 8627L-10, 8627L-18
  • SynchroMed II Implantable Infusion Pump, Models 8637-20, 8637-40,
  • IsoMed Implantable Infusion Pump, Models 8472-20, 8472-35, 8472-60.
The implantable components of the infusion systems listed above include the pump, a side catheter access port, catheters, and/or catheter accessories.
Use:

These devices administer drugs to a specific site in the body to treat pain, spasticity (continuous muscle contraction), and cancer. The pump is implanted in the patient, either with or without a side catheter access port, catheters, and catheter accessories.
Recalling Firm:
 Medtronic Neuromodulation
800 53rd Avenue NE
Minneapolis, Minnesota 55440-1250
Reason for Recall:

The company updated the labeling for the devices to include current patient management and treatment recommendations. The company also received reports of inflammatory mass formations at or near the distal tip of intrathecal catheters which infuse opioids, baclofen, or chemotherapy drugs into patients. For more detailed information, please see the link below to the company’s press release.

Public Contact:

Patients or customers may contact Medtronic Neuromodulation at 1-800-707-0933 from Monday - Friday, 7:00 a.m. – 6:00 p.m. (Central Standard Time) or by emailing the company at: http://www.medtronic.com/corporate/contact.jsp
FDA District:
 Minneapolis
FDA Comments:

On January 16, 2008, Medtronic sent a letter to doctors who implant these devices and/or provide care to patients with the implanted device. The letter described the problem, patient risks, patient management, recommendations and next steps.

For more information about this recall, including Medtronic's letter to physicians, please see the company’s press release at: http://wwwp.medtronic.com/Newsroom/ NewsReleaseDetails.do?itemId=1205958103681

Class 1 recalls are the most serious type of recall and involve situations in which there is a reasonable probability that use of the product will cause serious injury or death.

Health care professionals and consumers may report adverse reactions or quality problems experienced with the use of this product to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by FAX.

Updated March 28, 2008

horizonal rule

CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

Center for Devices and Radiological Health / CDRH